VFIC
HUMA icon

Valley Forge Investment Consultants’s Humacyte HUMA Stock Holding History

Valley Forge Investment Consultants’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,000
Closed -$36K – 80
2022
Q3 		$36K Hold
11,000
– – 0.02% 73
2022
Q2 		$35K Buy
+11,000
New +$61.2K 0.02% 72
2022
Q1 		– Sell
-11,000
Closed -$80K – 86
2021
Q4 		$80K Hold
11,000
– – 0.04% 74
2021
Q3 		$128K Buy
11,000
+1,000
+10% +$11.4K 0.07% 69
2021
Q2 		$102K Buy
+10,000
New +$103K 0.06% 70

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Valley Forge Investment Consultants's HUMA Position: Q4 2022 in Review

Valley Forge Investment Consultants sold out of Humacyte (HUMA) in Q4 2022, closing a stake of 11,000 shares — an estimated $36K sold.

Valley Forge Investment Consultants first reported a position in HUMA in Q2 2021 and held it in 5 quarters. The position peaked at $128K in Q3 2021. 75 funds tracked by Wall St. Rank hold HUMA as of Q4 2022.

  • Valley Forge Investment Consultants reported no remaining Humacyte position as of Q4 2022 after selling out during the quarter.
  • Valley Forge Investment Consultants sold 11,000 Humacyte shares in Q4 2022, an estimated $36K.
  • Valley Forge Investment Consultants first reported a position in Humacyte in Q2 2021 and held it in 5 quarters.
  • Valley Forge Investment Consultants's Humacyte position peaked at $128K in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Humacyte as of Q4 2022.

Based on Valley Forge Investment Consultants's 13F filing for Q4 2022, filed 14 Feb 2023.